StockDrifts LogoStockDrifts

ST Pharm 237690

Company
에스티팜ST Pharm
Insiders
2
Buys
1
Total Value
₩620M ($431K)
Avg Return
+51.16%
Last Filing
2026-04-24

ST Pharm (237690) has 1 disclosed insider purchases and 1 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩620M ($431K) in reported transaction value. The earliest filing StockDrifts holds for ST Pharm is dated 2024-06-19; the most recent is 2026-04-24. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +51.16%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-07-31BUYMarket Buy
최용훈
Yonghoon Choi
Planning Director350₩88,500+0.0%₩35M ($25K)
2026-04-24BUY주식매수선택권
최석우
Seokwoo Choi
Managing Director5.0K₩148,000+3.0%₩740M ($514K)
2026-04-24BUY주식매수선택권
임진석
Lim Jin-seok
Gyeongsan Factory Manager5.0K₩148,000+3.0%₩740M ($514K)
2026-04-03BUY주식매수선택권
윤정열
Yoon Jeong-yeol
Director of Quality Management Division4.7K₩138,100+0.7%₩642M ($446K)
2026-03-30SELLMarket Sell
임진석
Lim Jin-seok
Gyeongsan Factory Manager-3.6K₩148,800+6.6%₩543M ($377K)
2026-03-27SELL임원퇴임
김이환
Lee Hwan Kim
Planning Director-1.0K₩159,300+12.7%₩159M ($111K)
2026-03-19BUY주식매수청구권 행사
임진석
Lim Jin-seok
Gyeongsan Factory Manager3.6K₩149,500-7.0%₩546M ($379K)
2025-03-18BUYMarket Buy
김이환
Lee Hwan Kim
Head of Management Planning Department1.0K₩77,200+95.7%₩77M ($54K)
2024-08-20SELL시간외매매
강정석
Jeongseok Kang
--950.0K₩98,500-53.4%₩93.6B ($65.0M)
2024-06-19SELL임원퇴임
김경진
Kyungjin Kim
CEO and President-100₩92,300-63.7%₩9M ($6K)

Frequently asked questions

Who has been buying ST Pharm stock?
2 distinct insiders have filed 1 disclosed insider purchases in ST Pharm (237690), most recently on 2026-04-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does ST Pharm have?
ST Pharm has 1 buy-side and 1 sell-side disclosures on record, covering ₩620M ($431K) in total reported value, spanning 2024-06-19 to 2026-04-24.
Where does StockDrifts get ST Pharm insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for ST Pharm. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.